Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 66Carcinoma, Renal Cell 38Liver Neoplasms 20Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 16Neoplasms 15Breast Neoplasms 15Melanoma 13Thyroid Neoplasms 10Leukemia, Myeloid, Acute 10Sarcoma 9Lung Neoplasms 8Kidney Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 7Urinary Bladder Neoplasms 6Pancreatic Neoplasms 6Glioblastoma 6Brain Neoplasms 6Colorectal Neoplasms 5Carcinoma, Medullary 5Thyroid Carcinoma, Anaplastic 4Stomach Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Gallbladder Neoplasms 4Colonic Neoplasms 4Breast Neoplasms, Male 4Thyroid Diseases 3Thyroid Cancer, Papillary 3

Interventions

vandetanib 1lenvatinib 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid cancer, medullary × Sorafenib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡